May Measurement Month 2021: an analysis of blood pressure screening results from Venezuela
Author(s)
Hernández-Hernández, Rafael
Guzmán-Franulic, Mónica L
Rawik-Dagher, Yuly
Beaney, Thomas
Poulter, Neil R
Type
Journal Article
Abstract
Cardiovascular diseases continue to be the main cause of death in Venezuela, and hypertension is the principal risk factor. The May Measurement Month (MMM) campaign is a global initiative aimed to raising awareness of hypertension, which has been conducted in Venezuela since 2017. May Measurement Month 2021 included 46 732 participants with a mean age of 56.4 years (SD 14.4), 57.9% of whom were female. The percentage with hypertension was 60.3% (57.9% of females and 63.7% of males), 82.3% (84.8% of females and 79.2% of males) were aware, and 80.2% were taking antihypertensive medication. Of those on antihypertensive medication, 44.2% (41.2% of females and 48.2% of males) were not controlled [blood pressure (BP) ≥ 140/≥90 mmHg], with 61.3% receiving one drug, 30.0% two drugs, and 8.7% three or more drugs. 87.5% of those on treatment reported taking it regularly. Conditions associated with higher BP levels include fewer years of education, having a previous diagnosis of hypertension, and women who were hypertensive during a previous pregnancy. Physical activity and pregnancy were conditions associated with lower BP levels. A previous positive COVID-19 test was reported in 11.1%, and one or more COVID-19 vaccinations reported in 22.7% of participants. Of those on antihypertensive medication, 78.8% reported their treatment was not affected by COVID-19. Results are consistent with previous MMM campaigns and indicate that the screening campaign is feasible and useful to identify hypertension even in exceptional conditions such as the COVID-19 pandemic.
Date Issued
2024-06
Date Acceptance
2024-07-01
Citation
European Heart Journal Supplements, 2024, 26 (Supplement 3), pp.iii99-iii101
ISSN
1520-765X
Publisher
Oxford University Press
Start Page
iii99
End Page
iii101
Journal / Book Title
European Heart Journal Supplements
Volume
26
Issue
Supplement 3
Copyright Statement
© The Author(s) 2024. Published by Oxford University Press on behalf of the European Society of Cardiology.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://
creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium,
provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for
reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for
further information please contact journals.permissions@oup.com.
This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (https://
creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium,
provided the original work is properly cited. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for
reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for
further information please contact journals.permissions@oup.com.
License URL
Identifier
https://www.ncbi.nlm.nih.gov/pubmed/39055592
Subjects
Control
Hypertension
Screening
Treatment
Publication Status
Published
Coverage Spatial
England
Article Number
suae065
Date Publish Online
2024-07-24